Showcasing health innovation Dr Samus ONeill Chair AHSN Network, - - PowerPoint PPT Presentation

▶
showcasing
SMART_READER_LITE
LIVE PREVIEW

Showcasing health innovation Dr Samus ONeill Chair AHSN Network, - - PowerPoint PPT Presentation

Mar 20, 2023 276 likes •664 views

Showcasing health innovation Dr Samus ONeill Chair AHSN Network, CEO AHSN North East and North Cumbria Our strength lies in our local and national focus A bridge between national impact & local delivery Embedded in our local

slide-1
SLIDE 1

Showcasing health innovation

Dr Séamus O’Neill Chair AHSN Network, CEO AHSN North East and North Cumbria

slide-2
SLIDE 2

Our strength lies in our local and national focus

A bridge between national impact & local delivery Embedded in our local systems, we can work across sectors to understand & respond to needs A connected network, taking what works locally and spreading nationally A broker between the NHS & industry, and a trusted partner to signpost to solutions

slide-3
SLIDE 3

Our continuing mission is to spread healthcare innovation at pace and scale

slide-4
SLIDE 4
slide-5
SLIDE 5

PReCePT

slide-6
SLIDE 6

AF related strokes

slide-7
SLIDE 7

ITP – evidencing the AHSNs’ unique value

slide-8
SLIDE 8

188

additional jobs safeguarded

691

jobs created, more than

  • ur entire 1st

licence

2,605

companies supported by AHSNs

Economic growth impacts 2018-19

£152M

investment leveraged, £60M above

  • ur target
slide-9
SLIDE 9

Partnerships to enhance innovation in reducing the number

  • f AF related strokes

Dr Julia Reynolds - Associate Director and Head of Programmes, Innovation Agency (North West Coast AHSN) Dr Quincy Chuka, GPSI Cardiology and Clinical Lead LTC, NHS Warrington CCG

#AHSNs @AHSNNetwork

slide-10
SLIDE 10
  • 108,875 people expected to have AF yet only

93,446 are on the register

  • 15,429 undiagnosed people potentially not getting

appropriate treatment

  • 13,120 diagnosed people are not being treated with

anticoagulants

  • The proportion of patients on each GP register with

undetected AF varies across the CCGs

More people to find in the North West Coast

Protect Detect

slide-11
SLIDE 11

Fire & Rescue Services AF Ambassadors 1,595 tested 69 Possible AFs Public campaigns 1,346 tested 18 possible AFs GP practices over 300 devices to GPs

Morecambe, East Lancashire, Blackburn with Darwen, Blackpool, Fylde & Wyre, Warrington, Liverpool, Wirral

Detect initiatives in 2018… case finding with mobile ECGs

slide-12
SLIDE 12

The Innovation Agency response: The NWC Atrial Fibrillation Collaborative

68

practices

4

CCGs

across

Quality Improvement (QI) training and support Kardia mobile ECG devices GRASP-AF training Case-finding support AF clinical training and materials

Practice support included

AIMS

To have 80% of all high risk AF patients (CHADS2S-VASc>1) on anticoagulation therapy To close the prevalence gap between observed AF prevalence and the expected AF prevalence by 50% Practices worked through a driver diagram to generate improvement goals and change ideas

  • ver a

9 month project

Detect Protect

slide-13
SLIDE 13

Warrington CCG’S Atrial Fibrillation Collaborative: Sustainable approach

26

practices Population ~220 000

across

Quality Improvement (QI) training and support Kardia mobile ECG devices GRASP-AF training Incentive

  • £1500
  • DS & Pfizer

AF clinical training and materials

Practice support included

AIM

  • 85% of all GPs
  • 95% of all practice

pharmacists

  • 60% of all Nurses/ HCAs

Reduce variation between practices of Prevalence and anticoagulation of AF patients Improve clinician’s confidence

  • AF pathways
  • Templates

2 hour clinical session per practice

18 month project

Capacity

slide-14
SLIDE 14

Warrington CCG’S Atrial Fibrillation Collaborative

THE RESULTS THE IMPACT

794

patients added to AF registers

690

high risk AF patients initiated

  • n anticoagulation therapy

27.6

This initiative led to an estimated…

strokes saved per year

£480,000

Savings to the health system in year one alone

based on one stroke per 25 people not anticoagulated

Detect Protect

Savings over 5 Years

£2,400,030

Societal Cost Savings over 5 Years

£13.1 M

slide-15
SLIDE 15

PReCePT: protecting preterm babies from cerebral palsy

Dr Karen Luyt, Consultant Neonatologist, University Hospitals Bristol Natasha Swinscoe, CEO, West of England AHSN

#AHSNs @AHSNNetwork

slide-16
SLIDE 16
slide-17
SLIDE 17
  • 6 month quality improvement (QI) project with rapid

success

  • Increase in uptake in magnesium sulphate in all 5

units (81 – 100% use in eligible women)

  • Of 82 eligible births, 72 women received the

intervention (88% overall compliance)

  • Practice embedded and sustained

The birth of PReCePT

Gloucestershire Hospital Southmead Hospital St Michael’s Hospital Royal United Hospitals Bath Great Western Hospital

slide-18
SLIDE 18

PReCePT programme overview

2016 June 2018

  • Network approach
  • Delivered via the

AHSNs

  • Standardised

resources

  • 90 hours midwife

backfill per unit

  • Regional clinical lead
  • Target: 85% of

eligible mothers receive MgSO4 by March 2020

£1 million funding

Sep 2018

slide-19
SLIDE 19
slide-20
SLIDE 20

PReCePT programme: progress so far

  • 121 maternity trusts
  • 79.5% uptake of MgSO4
slide-21
SLIDE 21

PReCePT programme: progress so far

slide-22
SLIDE 22

PReCePT programme: progress so far

PReCePT is endorsed by… and features in…

slide-23
SLIDE 23

Find out more: www.ahsnnetwork/PReCePT Follow us on Twitter: Programme: @PReCePT_MgSO4 Study: @PReCePT_study

slide-24
SLIDE 24

EMAHSN and Qbtech Transforming ADHD Care in the East Midlands

Tony Doyle Managing Director, Qbtech Ltd

#AHSNs @AHSNNetwork

slide-25
SLIDE 25

Improving diagnosis of ADHD in children

ADHD – Commonly occurring, severely impairing, yet very responsive to treatment

  • Chronic neurodevelopmental disorder affecting

5% of children

  • Most cases diagnosed in 6-12 years olds – ten

fold increase since 1980s

  • Characterised by a persistent pattern of

inattention and/or hyperactivity and impulsivity

  • Can lead to; poor educational progress,

accidents, poor employability, sleep and anxiety disorders, a range of social issues and reliance

  • n health and social care
  • Costs the NHS at least £23m each year in

specialist assessments to inform diagnosis QbTest – Digital test of sustained attention with motion capture to measure core indicator symptoms of ADHD

  • The only CE marked, European Medicines Agency

(EMA) registered and Food and Drug Administration (FDA) cleared intervention that simultaneously measures: Attention, impulsivity and motor activity, the core requirements of diagnostic criteria in both DSMIV and ICD10

  • Performance is compared to an age and gender

matched normative control group

  • Provides objective, quality, unbiased information
  • Cuts through ambiguity, standardises clinical

practice, measures effectiveness of treatment

slide-26
SLIDE 26

Family and clinician experience of ADHD

slide-27
SLIDE 27

QbTest

slide-28
SLIDE 28

Outcomes

  • Time from assessment to diagnosis reduced by 153 days
  • Released 20% clinical workforce time
  • Cost reductions (efficiency) of 32.6% / ROI = £84,460
  • 85% of patients found the QbTest results helpful
  • 94% of clinicians reported greater understanding of patients symptoms
  • QbTest sustainability in all three Trusts beyond funded demonstrator
  • 41 Trusts currently deploying QbTests across 73 sites in England
slide-29
SLIDE 29

EMAHSN support

Funding of 12 month ‘real world’ demonstrator in three Trusts across six sites in the East Midlands. But just as important:

  • Metrics – evaluation
  • Accountability and monitoring – steering group
  • Capacity / resource – project manager and boots on the ground
  • Independent evaluation – different pathway models
  • Credibility – NHS leverage
  • Adoption and spread – stakeholder mapping / ongoing partnership
  • Communications – high quality targeted comms
slide-30
SLIDE 30

For more information please contact:

Dara Coppel EMAHSN, Head of Innovation Programme Delivery 07917 220 140 l dara.coppel@nottingham.ac.uk Tony Doyle Qbtech Limited, Managing Director 07771 937 845 www.qbtech.com | @QbtechADHD www.emahsn.org.uk | @EM_AHSN

slide-31
SLIDE 31

Digital Transformation

  • f Continuing

Healthcare

Charles MacKinnon NIA Fellow Healthcare Director IEG4 Ltd

#AHSNs @AHSNNetwork

slide-32
SLIDE 32
  • DToC Focus
  • NAO report
  • Digital a key

enabler

National Improvement Priority

slide-33
SLIDE 33
  • Content
  • Abc
  • Xyz

Collaboration, collaboration… repeat

Increasing Involvement Fast Followers Lead NHS Cohort

slide-34
SLIDE 34

Digital CHC

Streamlined Workflow With no paperwork

Simple Back Office With intuitive functions

slide-35
SLIDE 35

NHS Innovation Assurance

Innovation & Technology Payment Programme

A high-scoring, eminently usable system that greatly impressed all of our assessors in terms especially of clinical efficacy, safety, security and privacy. OurMobileHealth.com Digital Service Assessors for NHS ITP identifies and Encourages NHS To Adopt Proven Innovations IEG4’s CHC2DST 1 of 10 finalists

slide-36
SLIDE 36

Health and Care Innovation Adoption

Promoting the “it’s a contact sport”! Funding and managing independent evaluation Following the adoption at scale model for GM

slide-37
SLIDE 37

Panel Q&A

#AHSNs @AHSNNetwork

slide-38
SLIDE 38

Dr Séamus O’Neill - Chair AHSN Network, CEO AHSN North East and North Cumbria Dr Julia Reynolds - Associate Director and Head

  • f Programmes, Innovation Agency

Dr Quincy Chuka - GPSI Cardiology and Clinical Lead Long Term Conditions, NHS Warrington CCG Dr Karen Luyt - Consultant Neonatologist, University Hospitals Bristol Natasha Swinscoe - CEO, West of England AHSN Tony Doyle - Managing Director, Qbtech Ltd Charles MacKinnon - NIA Fellow and Healthcare Director IEG4 Ltd

#AHSNs @AHSNNetwork